Flotetuzumab - CAS 1664355-28-5

Flotetuzumab (MGD006; S80880), an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule, reactivates T cells through concurrent engagement with CD123 on target cells and CD3 on effector T cells, facilitating T-cell-mediated cytotoxicity in target cells. Demonstrating an inhibitory effect in a mouse model of patient-derived xenograft (PDX) for acute myeloid leukemia (AML) [1] [2], Flotetuzumab offers potential therapeutic prospects for AML treatment.

Integrin

Cytoskeletal Signaling

1664322

-20°C

Ice Packs

Inhibitory Antibodies